326.4 📋 章末速記 Summary

326.4.1 🔑 一句話總結

SCLC = 15% of lung cancer，almost exclusively smokers，aggressive central neuroendocrine tumor with TP53 + RB1 mutations universal；staging = LS-SCLC (one hemithorax, single radiation field) vs ES-SCLC；LS-SCLC：concurrent chemoradiation (cisplatin + etoposide + 45 Gy BID) + PCI for CR；ES-SCLC：carboplatin + etoposide + atezolizumab (IMpower133 2018) or durvalumab (CASPIAN 2019)；ADRIATIC 2024 確立 durvalumab consolidation in LS-SCLC；refractory SCLC：tarlatamab (Imdelltra) DLL3-targeted BiTE — DeLLphi-301 2024, FDA approval — 40% response rate, game-changer；lurbinectedin (2020 FDA), topotecan；paraneoplastic syndromes：SCLC (SIADH 10% + Cushing-ACTH 5% + LEMS-anti-VGCC + limbic encephalitis-anti-Hu)；squamous (PTHrP hypercalcemia)；adenocarcinoma (HPOA + clubbing)；Trousseau (hypercoagulability any cancer)；neuroendocrine tumor spectrum：typical carcinoid (slow, surgery curative) → atypical carcinoid → LCNEC → SCLC (most aggressive)；LEMS vs MG：LEMS improves with effort + anti-VGCC + autonomic; MG worsens + anti-AChR + thymoma association。

326.4.2 💊 治療精要

  • LS-SCLC：concurrent chemoradiation (cisplatin + etoposide × 4-6 cycles + radiation 45 Gy BID or 60-70 Gy daily) + PCI (prophylactic cranial irradiation 25 Gy / 10 fractions) for complete response
  • ES-SCLC：carboplatin + etoposide + atezolizumab (IMpower133) OR durvalumab (CASPIAN) × 4 cycles → maintenance IO
  • LS-SCLC + durvalumab consolidation (ADRIATIC 2024)：emerging post-chemoradiation
  • refractory SCLC 2nd-line+：tarlatamab (DLL3 BiTE) — DeLLphi-301 2024 FDA, 40% response, game-changing；lurbinectedin (Zepzelca, 2020 FDA, 35% response)；topotecan
  • paraneoplastic SIADH：fluid restriction, tolvaptan, demeclocycline
  • paraneoplastic Cushing：ketoconazole, metyrapone, mitotane, etomidate, mifepristone
  • LEMS：3,4-diaminopyridine + IVIG + plasmapheresis + treat underlying cancer
  • limbic encephalitis：IVIG + plasmapheresis + IS + treat underlying cancer
  • carcinoid tumors：surgical resection (typical 90%+ cure rate)；octreotide / lanreotide for carcinoid syndrome
  • brain mets：WBRT, SRS, hippocampal avoidance protocols

326.4.3 🎯 盧醫師的考前提醒

  1. SCLC 三大特徵：almost exclusively smokers + aggressive (rapid growth, 30-day doubling) + neuroendocrine (chromogranin, synaptophysin, CD56, INSM1) + TP53 + RB1 universal
  2. LS-SCLC vs ES-SCLC：LS = one hemithorax + single radiation field；ES = beyond (contralateral lung, distant mets); chemoradiation + PCI 顯著改善 LS-SCLC 結果
  3. PCI (prophylactic cranial irradiation)：LS-SCLC + complete response → 25 Gy × 10 fractions → ↑ survival；ES-SCLC PCI 較有爭議
  4. IMpower133 (2018) + CASPIAN (2019)：atezolizumab + durvalumab + chemo for ES-SCLC → median OS 12-13 months vs 10 months chemo alone
  5. ADRIATIC (2024)：durvalumab consolidation in LS-SCLC after chemoradiation → 預計改寫 LS-SCLC SOC
  6. TARLATAMAB (Imdelltra) DLL3 BiTE 2024 FDA：第一個 SCLC immunotherapy 顯示 dramatic response (40%) in pretreated；DeLLphi-301 trial；watch for cytokine release syndrome + neurotoxicity (ICANS)
  7. paraneoplastic syndromes 經典：SCLC = SIADH + Cushing (ACTH) + LEMS + limbic encephalitis；squamous = PTHrP → hypercalcemia；adenocarcinoma = HPOA + clubbing
  8. LEMS vs MG 鑑別重要：LEMS improves with effort + autonomic + anti-VGCC + SCLC association；MG worsens + anti-AChR + thymoma association；EMG: LEMS facilitation at high freq, MG decrement at low freq
  9. neuroendocrine tumor spectrum：typical carcinoid (well-diff, < 2 mitoses, surgical cure)、atypical carcinoid (mod, 2-10 mitoses)、LCNEC (poor, > 10 mitoses)、SCLC (most poor, > 11 mitoses); 從 indolent → aggressive
  10. carcinoid heart disease：5-HT 在 lung 代謝；右側 valves (tricuspid, pulmonic) affected；mesh-like fibrosis；echo + valve surgery if severe；octreotide for prevention/control of carcinoid syndrome